Biomarkers for the clinical management of breast cancer: International perspective
Open Access
- 20 December 2012
- journal article
- review article
- Published by Wiley in International Journal of Cancer
- Vol. 133 (1), 1-13
- https://doi.org/10.1002/ijc.27997
Abstract
The higher incidence of breast cancer in developed countries has been tempered by reductions in mortality, largely attributable to mammographic screening programmes and advances in adjuvant therapy. Optimal systemic management requires consideration of clinical, pathological and biological parameters. Oestrogen receptor alpha (ERα), progesterone receptor (PgR) and human epidermal growth factor receptor 2 (HER2) are established biomarkers evaluated at diagnosis, which identify cardinal subtypes of breast cancer. Their prognostic and predictive utility effectively guides systemic treatment with endocrine, anti‐HER2 and chemotherapy. Hence, accurate and reliable determination remains of paramount importance. However, the goals of personalized medicine and targeted therapies demand further information regarding residual risk and potential benefit of additional treatments in specific circumstances. The need for biomarkers which are fit for purpose, and the demands placed upon them, is therefore expected to increase. Technological advances, in particular high‐throughput global gene expression profiling, have generated multi‐gene signatures providing further prognostic and predictive information. The rational integration of routinely evaluated clinico‐pathological parameters with key indicators of biological activity, such as proliferation markers, also provides a ready opportunity to improve the information available to guide systemic therapy decisions. The additional value of such information and its proper place in patient management is currently under evaluation in prospective clinical trials. Expanding the utility of biomarkers to lower resource settings requires an emphasis on cost effectiveness, quality assurance and possible international variations in tumor biology; the potential for improved clinical outcomes should be justified against logistical and economic considerations.This publication has 103 references indexed in Scilit:
- Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657)Breast Cancer Research and Treatment, 2011
- HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient dataThe Lancet Oncology, 2011
- Prognostic role of CA15.3 in 7942 patients with operable breast cancerBreast Cancer Research and Treatment, 2011
- Quality assessment of HER2 testing by monitoring of positivity ratesVirchows Archiv A Pathological Anatomy and Histopathology, 2011
- Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trialThe Lancet Oncology, 2010
- Modeling the relationship between circulating tumour cells number and prognosis of metastatic breast cancerBreast Cancer Research and Treatment, 2009
- Defining a global research agenda for breast cancerCancer, 2008
- Breast cancer patients with estrogen receptor-negative/progesterone receptor-positive tumors: being younger and getting less benefit from adjuvant tamoxifen treatmentZeitschrift für Krebsforschung und Klinische Onkologie, 2008
- Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trialsThe Lancet, 2005
- Gene expression profiling predicts clinical outcome of breast cancerNature, 2002